IN2012DN06588A - - Google Patents

Info

Publication number
IN2012DN06588A
IN2012DN06588A IN6588DEN2012A IN2012DN06588A IN 2012DN06588 A IN2012DN06588 A IN 2012DN06588A IN 6588DEN2012 A IN6588DEN2012 A IN 6588DEN2012A IN 2012DN06588 A IN2012DN06588 A IN 2012DN06588A
Authority
IN
India
Prior art keywords
fbxo40
antagonist
muscle mass
patient
methods
Prior art date
Application number
Inventor
David Glass
Jun Shi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2012DN06588A publication Critical patent/IN2012DN06588A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)

Abstract

The disclosure relates to treating muscle wasting associated disorders in a patient using a therapeutically effective amount of an antagonist of Fbxo40 wherein the antagonist reduces the expression level or activity of Fbxo40. The Fbxo40 antagonist increases muscle mass or prevents limits or reduces muscle mass loss in the patient. The Fbxo40 antagonist can be a low molecular weight (LMW) compound a protein an antibody or an inhibitory nucleic acid such as a siRNA. The disclosure also relates to methods of screening for antagonists of Fbxo40 and methods of diagnosing or monitoring levels of muscle mass maintenance loss or increase.
IN6588DEN2012 2010-02-10 2011-02-08 IN2012DN06588A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30302710P 2010-02-10 2010-02-10
PCT/EP2011/051825 WO2011098449A1 (en) 2010-02-10 2011-02-08 Methods and compounds for muscle growth

Publications (1)

Publication Number Publication Date
IN2012DN06588A true IN2012DN06588A (en) 2015-10-23

Family

ID=44169195

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6588DEN2012 IN2012DN06588A (en) 2010-02-10 2011-02-08

Country Status (12)

Country Link
US (1) US20120296403A1 (en)
EP (1) EP2534489A1 (en)
JP (1) JP2013519869A (en)
KR (1) KR20120125357A (en)
CN (1) CN102770767A (en)
AU (1) AU2011214465A1 (en)
BR (1) BR112012019902A2 (en)
CA (1) CA2789125A1 (en)
EA (1) EA201201113A1 (en)
IN (1) IN2012DN06588A (en)
MX (1) MX2012009318A (en)
WO (1) WO2011098449A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148740A1 (en) * 2012-03-26 2013-10-03 The Trustees Of Columbia University In The City Of New York 4–aminopyridine as a therapeutic agent for spinal muscular atrophy
WO2014119634A1 (en) * 2013-01-30 2014-08-07 独立行政法人国立精神・神経医療研究センター Muscle-building agent, and pharmaceutical composition containing same
ES2698363T3 (en) * 2013-03-14 2019-02-04 Actimed Therapeutics Ltd Compositions of oxprenolol to treat cancer
CA2904119C (en) 2013-03-14 2018-01-02 Abbott Laboratories Treatment of insulin resistance associated with prolonged physical inactivity
DK2986156T3 (en) * 2013-04-15 2017-02-20 Nestec Sa USE OF WHEEL PROTEIN IN COMBINATION WITH ELECTRICAL MUSCLE STIMULATION
WO2015050160A1 (en) * 2013-10-03 2015-04-09 国立大学法人大阪大学 Anti-aging pharmaceutical composition for muscle containing as active ingredient parathyroid hormone or derivative thereof
JP6566520B2 (en) * 2013-10-29 2019-08-28 国立大学法人 熊本大学 Pharmaceutical composition for the treatment or prevention of muscle disease
WO2015119249A1 (en) * 2014-02-07 2015-08-13 国立大学法人東京医科歯科大学 Myogenesis accelerator, amyotrophy suppressor, medicinal composition, and taz activator
WO2016058919A1 (en) * 2014-10-14 2016-04-21 Nestec S.A. Improvement in muscle functionality of elderly males
SG11201808981XA (en) * 2016-04-14 2018-11-29 Benitec Biopharma Ltd Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
CN105821049B (en) * 2016-04-29 2019-06-04 中国农业大学 A kind of preparation method of Fbxo40 gene knock-out pig
EP3952849A4 (en) * 2019-04-12 2023-03-01 The Regents Of The University Of California Compositions and methods for increasing muscle mass and oxidative metabolism

Family Cites Families (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696561B1 (en) 1909-07-09 2004-02-24 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ES2052027T5 (en) 1988-11-11 2005-04-16 Medical Research Council IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING.
ATE135370T1 (en) 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5789157A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5864026A (en) 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5712375A (en) 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5763566A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
CA2093664C (en) 1990-10-12 2003-07-29 Fritz Eckstein Modified ribozymes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
DE4216134A1 (en) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
DE69233087T2 (en) 1991-11-22 2003-12-24 Affymetrix Inc N D Ges D Staat Process for the production of polymer arrays
EP0616640B1 (en) 1991-12-02 2004-09-01 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
ATE275198T1 (en) 1991-12-02 2004-09-15 Medical Res Council PRODUCTION OF ANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES.
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK0656946T4 (en) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobulins without light chains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JPH08511420A (en) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド Body
US6448373B1 (en) 1994-01-11 2002-09-10 Isis Pharmaceuticals, Inc. Phosphate linked oligomers formed of monomeric diols and processes for preparing same
SE9400088D0 (en) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5716824A (en) 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
ATE274520T1 (en) 1995-05-03 2004-09-15 Gilead Sciences Inc SYSTEMATIC EVOULTION OF LIGANDS THROUGH EXPONENTIAL ENHANCEMENT: TISSUE-SELEX
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
DE69637256T2 (en) 1996-01-16 2008-06-19 Sirna Therapeutics, Inc., Boulder Synthesis of methoxynucleosides and enzymatic nucleic acid molecules
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
US5792613A (en) 1996-06-12 1998-08-11 The Curators Of The University Of Missouri Method for obtaining RNA aptamers based on shape selection
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6617114B1 (en) 1996-10-31 2003-09-09 Karo Bio Ab Identification of drug complementary combinatorial libraries
US6421612B1 (en) 1996-11-04 2002-07-16 3-Dimensional Pharmaceuticals Inc. System, method and computer program product for identifying chemical compounds having desired properties
DE19649359C1 (en) 1996-11-28 1998-02-12 Thomas Prof Dr Peters Detecting biologically active substances in substance libraries
EP0971946B1 (en) 1997-01-21 2006-07-05 The General Hospital Corporation Selection of proteins using rna-protein fusions
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020165363A1 (en) 1997-05-15 2002-11-07 Koh Sato Cachexia remedy
ES2258817T3 (en) 1997-05-21 2006-09-01 Biovation Limited METHOD FOR THE PRODUCTION OF NON-IMMUNOGEN PROTEINS.
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6033860A (en) 1997-10-31 2000-03-07 Affymetrix, Inc. Expression profiles in adult and fetal organs
EP1049803A4 (en) 1997-12-15 2002-08-21 Nexstar Pharmaceuticals Inc Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
ATE526406T1 (en) 1998-03-20 2011-10-15 Commw Scient Ind Res Org CONTROL OF GENE EXPRESSION
US6720190B1 (en) 1998-03-27 2004-04-13 Ole Hindsgaul Methods for screening compound libraries
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
CA2240325A1 (en) 1998-03-27 1998-11-14 Synsorb Biotech, Inc. Methods for screening compound libraries
US6054047A (en) 1998-03-27 2000-04-25 Synsorb Biotech, Inc. Apparatus for screening compound libraries
US6613575B1 (en) 1998-03-27 2003-09-02 Ole Hindsgaul Methods for screening compound libraries
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138668A0 (en) 1998-04-03 2001-10-31 Phylos Inc Addressable protein arrays
CN1202246C (en) 1998-04-08 2005-05-18 联邦科学和工业研究组织 Methods for means for obtaining modified phenotypes
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6458559B1 (en) 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
US6846655B1 (en) 1998-06-29 2005-01-25 Phylos, Inc. Methods for generating highly diverse libraries
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
US6312927B1 (en) 1998-08-17 2001-11-06 Phylos, Inc. Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular RNA-protein fusion formation
ATE437844T1 (en) 1998-08-17 2009-08-15 Bristol Myers Squibb Co IDENTIFICATION OF COMPOUND-PROTEIN INTERACTIONS WITH LIBRARIES OF COUPLED PROTEIN-NUCLIC ACID MOLECULES
US6194402B1 (en) 1998-09-02 2001-02-27 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
ATE457169T1 (en) 1998-10-15 2010-02-15 Imp Innovations Ltd COMPOUNDS FOR THE TREATMENT OF WEIGHT LOSS
US6187923B1 (en) 1998-11-09 2001-02-13 Axys Advanced Technologies, Inc. Process for the synthesis of quinazolinones
US6416950B1 (en) 1998-12-02 2002-07-09 Phylos, Inc. DNA-protein fusions and uses thereof
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR100940380B1 (en) 1999-01-15 2010-02-02 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
EP1147204A1 (en) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
ES2571230T3 (en) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedure to control the activity of an immunofunctional molecule
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
WO2000072869A1 (en) 1999-06-01 2000-12-07 Phylos, Inc. Methods for producing 5'-nucleic acid-protein conjugates
JP2003504061A (en) 1999-07-09 2003-02-04 ワイス Methods and compositions for preventing formation of aberrant RNA during transcription of plasmid sequences
WO2001004265A2 (en) 1999-07-12 2001-01-18 Phylos, Inc. C-terminal protein tagging
DE60034566T2 (en) 1999-07-27 2008-01-03 Adnexus Therapeutics, Inc., Waltham PEPTIDE RECEPTOR LIGATION PROCEDURE
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
CA2382545C (en) 1999-08-27 2013-08-13 Phylos, Inc. Methods for encoding and sorting in vitro translated proteins
US20030044846A1 (en) 2001-04-03 2003-03-06 Gary Eldridge Screening of chemical compounds purified from biological sources
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
JP2003516124A (en) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ RNA interference pathway genes as a means of targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10100586C1 (en) 2001-01-09 2002-04-11 Ribopharma Ag Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
DE10160151A1 (en) 2001-01-09 2003-06-26 Ribopharma Ag Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang
AU1767301A (en) 1999-11-29 2001-06-04 Cold Spring Harbor Laboratory Regulation of polycomb group gene expression for increasing seed size in plants
RU2164944C1 (en) 1999-12-09 2001-04-10 Институт молекулярной биологии им. В.А. Энгельгардта РАН Method of alternation of organism genetic features
WO2001049844A1 (en) 1999-12-30 2001-07-12 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
IT1316982B1 (en) 2000-01-17 2003-05-26 Univ Roma ISOLATION AND CHARACTERIZATION OF A GENE FOR GENE SILENCE N.CRASSA AND ITS USES.
CN1319761A (en) 2000-03-15 2001-10-31 清华大学 Apparatus and method for high-flux electric rotation detection
EP1266218A2 (en) 2000-03-15 2002-12-18 Aviva Biosciences Corporation Apparatus and method for high throughput electrorotation analysis
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
AU2001240375A1 (en) 2000-03-17 2001-10-03 Benitec Australia Limited Genetic silencing
AU2001260140A1 (en) 2000-03-22 2001-10-03 Avntis Pharma Deutschland Gmbh Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene.
GB0007268D0 (en) 2000-03-24 2000-05-17 Cyclacel Ltd Cell cycle progression proteins
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2001092513A1 (en) 2000-05-30 2001-12-06 Johnson & Johnson Research Pty Limited METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
IL143942A0 (en) 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
DK1334123T3 (en) 2000-11-09 2009-01-12 Cenix Bioscience Gmbh Eukaryotic cell division genes and their use in the diagnosis and treatment of proliferative diseases
HU230458B1 (en) 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Rna interference mediating small rna molecules
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DK1456360T3 (en) 2001-04-19 2015-08-31 Scripps Research Inst Methods and Composition for Preparation of Orthogonal TRNA-Aminoacyl-TRNA Synthetase Pairs
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
WO2002100435A1 (en) 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
AU2002310502A1 (en) 2001-06-21 2003-01-08 Phylos, Inc. In vitro protein interaction detection systems
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
FR2827518B1 (en) 2001-07-17 2005-07-08 Sod Conseils Rech Applic USE OF GINKGO BILOBA EXTRACTS FOR PREPARING A MEDICAMENT FOR THE TREATMENT OF SARCOPENIA
US20030027194A1 (en) 2001-07-31 2003-02-06 Markus Kurz Modular assembly of nucleic acid-protein fusion multimers
FR2828208A1 (en) * 2001-08-01 2003-02-07 Cytomics Systems New nucleic acids encoding F-box proteins, useful e.g. for treatment of cancer or inflammation, also new proteins, antibodies and modulators
DE60236520D1 (en) 2001-08-16 2010-07-08 Univ Pennsylvania SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFEKTION AND / OR PRODRUG AND MEDICAMENT THERAPIES WITH SLOW RELEASE
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US7125669B2 (en) 2001-11-27 2006-10-24 Compound Therapeutics, Inc. Solid-phase immobilization of proteins and peptides
WO2003064625A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Oligonucleotide compositions with enhanced efficiency
US6936427B2 (en) 2002-02-08 2005-08-30 Trellis Bioscience, Inc. Real time detection of intermolecular interaction
ATE328906T1 (en) 2002-06-28 2006-06-15 Domantis Ltd DUAL-SPECIFIC LIGANDS WITH INCREASED HALF-LIFE
WO2004002453A1 (en) 2002-06-28 2004-01-08 Protiva Biotherapeutics Ltd. Method and apparatus for producing liposomes
AU2003279010A1 (en) 2002-09-28 2004-04-19 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering rna and short hairpin rna
US20040259155A1 (en) 2002-09-30 2004-12-23 Compound Therapeutics, Inc. Methods of engineering spatially conserved motifs in polypeptides
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
DE60332277D1 (en) 2002-11-26 2010-06-02 Univ Massachusetts ADMINISTRATION OF SIRNAS
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20040208921A1 (en) 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
WO2004101790A1 (en) 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
RU2399671C2 (en) 2003-08-28 2010-09-20 Новартис Аг Rna duplex capable of interference and having blunt ends and 3'-modifications
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
CA2554218A1 (en) 2004-02-05 2005-08-18 Novartis Ag Screening assays
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
JP2008520207A (en) 2004-11-16 2008-06-19 アヴィディア リサーチ インスティテュート Protein backbone and uses thereof
US7429482B2 (en) * 2005-01-13 2008-09-30 United States Of America As Represented By The Department Of Veterans Affairs Screening tools for discovery of novel anabolic agents
WO2006079372A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc Proteinaceous pharmaceuticals and uses thereof
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
DK1957061T3 (en) 2005-11-30 2011-07-25 Novartis Pharma Gmbh A combination comprising at least one amino acid and a PKR inhibitor for use in the treatment of muscle wasting
US7442706B2 (en) 2006-03-15 2008-10-28 Thorner Michael O Methods for treating sarcopenia with a growth hormone secretagogue
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
US8240498B2 (en) 2006-10-31 2012-08-14 Crown Packaging Technology, Inc. Resealable closure
US20080108145A1 (en) * 2006-11-07 2008-05-08 Stephanie Chissoe Genes associated with osteoarthritis
US20100291551A1 (en) * 2006-11-17 2010-11-18 Genizon Biosciences Inc. Genemap of the human associated with crohn's disease
CN101616934A (en) * 2006-12-22 2009-12-30 健泰科生物技术公司 Suppress DR6 antibody and the purposes in treatment neuroscience illness thereof of DR6 in conjunction with APP
JP6776582B2 (en) 2016-03-31 2020-10-28 Tdk株式会社 Electronic components
US11054998B1 (en) 2019-12-12 2021-07-06 Facebook, Inc. High bandwidth memory system with distributed request broadcasting masters

Also Published As

Publication number Publication date
MX2012009318A (en) 2012-09-07
KR20120125357A (en) 2012-11-14
EP2534489A1 (en) 2012-12-19
BR112012019902A2 (en) 2019-09-24
EA201201113A1 (en) 2013-03-29
US20120296403A1 (en) 2012-11-22
AU2011214465A1 (en) 2012-08-30
CA2789125A1 (en) 2011-08-18
JP2013519869A (en) 2013-05-30
WO2011098449A1 (en) 2011-08-18
CN102770767A (en) 2012-11-07

Similar Documents

Publication Publication Date Title
IN2012DN06588A (en)
WO2013096407A3 (en) Monitoring activation times for use in determining pacing effectiveness
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
TW200716171A (en) Methods for treating and preventing fibrosis
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
JO3149B1 (en) Compositions and methods of use for therapeutic antibodies
MX353186B (en) Methods for treating, diagnosing, and monitoring rheumatoid arthritis.
WO2012118750A3 (en) Biological markers and methods for predicting response to b-cell antagonists
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
IN2012DN02177A (en)
IN2012DN00754A (en)
AR084373A1 (en) COMPOSITIONS AND METHODS FOR THE ELIMINATION OF BIOPELLICLES
EA201400623A1 (en) NEW 2H-INDASOLS AS ANTAGONISTS EP EPCEPTOR
MY157319A (en) Inhibitors of protein tyrosine kinase activity
NZ702178A (en) Lingo-2 antagonists for treatment of conditions involving motor neurons
WO2010112458A8 (en) Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
TR201909158T4 (en) siRNA and its use in methods and compositions for the treatment and / or prevention of eye disorders.
AU2012313353A8 (en) Screening method
TR201900438T4 (en) Non-acylated ghrelin fragments for use in the treatment of Prader-willi syndrome.
WO2011156000A3 (en) Use of il-4/il-13 antagonists to treat eosinophilic disorders
MX2012015112A (en) Use of a2b adenosine receptor antagonists for treating pulmonary hypertension.
EA201490623A1 (en) Antagonists of toll-like receptor 3 for the treatment of metabolic and cardiovascular diseases
EP2665488A4 (en) Methods and kits for assessing heparanase procoagulant activity, compositions comprising heparanase, and methods for the treatment of coagulation-related disorders
WO2012129395A3 (en) Diagnosis and treatment of prostate cancer